These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36579197)

  • 1. Grade III Severe QT Prolongation in an Indian Male on All-Oral Longer Regimen for Multidrug-Resistant Pulmonary Tuberculosis: World's First Case.
    Yadav S
    Cureus; 2022 Nov; 14(11):e31819. PubMed ID: 36579197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study.
    Liu F; Gao J; Gao M; Liu Y; Shu W; Xie L; Sun Y; Zhang L; Li L; Pang Y
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0203321. PubMed ID: 36047781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients.
    Ardhianto D; Suharjono ; Soedarsono ; Fatmawati U
    J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):421-427. PubMed ID: 34214323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scoping review: QT interval prolongation in regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis.
    Putra ON; Yulistiani Y; Soedarsono S
    Int J Mycobacteriol; 2022; 11(4):349-355. PubMed ID: 36510917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of anti-tuberculosis drug pharmacokinetics on QTc prolongation.
    Jin Y; Benkeser D; Kipiani M; Maranchick NF; Mikiashvili L; Barbakadze K; Avaliani Z; Alghamdi WA; Alshaer MH; Peloquin CA; Blumberg HM; Kempker RR
    Int J Antimicrob Agents; 2023 Oct; 62(4):106939. PubMed ID: 37517627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial.
    Motta I; Cusinato M; Ludman AJ; Lachenal N; Dodd M; Soe M; Abdrasuliev T; Usmanova R; Butabekov I; Nikolaevna TZ; Liverko I; Parpieva N; Moodliar R; Solodovnikova V; Kazounis E; Nyang'wa B-T; Fielding KL; Berry C
    Antimicrob Agents Chemother; 2024 Jul; 68(7):e0053624. PubMed ID: 38842323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical analysis of adverse reactions in patients with multidrug-resistant and rifampicin-resistant pulmonary tuberculosis treated with delamanid-containing regimen].
    Gao MQ; Gao JT; Ma XG; Shu W; Du J; Liang RX; Wu GH; Pei Y; Yan XF; Cai QS; Lyu KY; Cai C; Wu YQ; Li XJ; Liu QQ; Jin L; Wu QH; Xiong Y; Li MW; Zhou YQ; Kuang HB; Wang XF; Ren F; Chen XH; Geng SJ; Zhou Y; Sha W; Yang GL; Wang H; Zhan Y; Liu YH; Li L
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Jul; 47(7):638-646. PubMed ID: 38955749
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. INCIDENCE OF HIGH GRADE QTCF PROLONGATION AND ITS MANAGEMENT AMONG PATIENTS UNDERGOING TREATMENT FOR DRUG RESISTANT TUBERCULOSIS (DR-TB): CASE SERIES.
    Asfaw MT; Holtzman DL; Kwan GF; Oyewusi LT; Mitnick CD; Seung KJ
    Afr J Infect Dis; 2021; 15(2 Suppl):38-41. PubMed ID: 34595385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies.
    Ali AM; Radtke KK; Hesseling AC; Winckler J; Schaaf HS; Draper HR; Solans BP; van der Laan L; Hughes J; Fourie B; Nielsen J; Garcia-Prats AJ; Savic RM
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0144822. PubMed ID: 37358463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy Volunteers.
    Li M; Saviolakis GA; El-Amin W; Makhene MK; Osborn B; Nedelman J; Yang TJ; Everitt D
    Clin Pharmacol Drug Dev; 2021 Jun; 10(6):634-646. PubMed ID: 33378139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QT prolongation in the STREAM Stage 1 Trial.
    Hughes G; Bern H; Chiang CY; Goodall RL; Nunn AJ; Rusen ID; Meredith SK
    Int J Tuberc Lung Dis; 2022 Apr; 26(4):334-340. PubMed ID: 35351238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV and body mass index are associated with prolonged corrected QT interval among people with drug-resistant tuberculosis on bedaquiline-containing regimen in Uganda.
    Lodiong LJD; Izudi J; Amos T; Twinomugisha B; Kulaba N; Lumori BAE
    IJID Reg; 2024 Dec; 13():100438. PubMed ID: 39403274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety.
    Gao JT; Du J; Wu GH; Pei Y; Gao MQ; Martinez L; Fan L; Chen W; Xie L; Chen Y; Wang H; Jin L; Li GB; Zong PL; Xiong Y; Wu QH; Li MW; Yan XF; Miao YF; Cai QS; Li XJ; Bai DP; Geng SJ; Yang GL; Tang PJ; Zeng Y; Chen XH; Li TX; Cai C; Zhou Y; Zhuo M; Wang JY; Guan WL; Xu L; Shi JC; Shu W; Cheng LL; Teng F; Ning YJ; Xie SH; Sun YX; Zhang LJ; Liu YH
    Infect Dis Poverty; 2021 Mar; 10(1):32. PubMed ID: 33736710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis.
    Olayanju O; Esmail A; Limberis J; Dheda K
    Eur Respir J; 2020 Jan; 55(1):. PubMed ID: 31619478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic investigational new drugs for the treatment of tuberculosis.
    Kwon YS; Koh WJ
    Expert Opin Investig Drugs; 2016; 25(2):183-93. PubMed ID: 26576631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline glycated hemoglobin and potassium level correlated with pretreatment QT-corrected interval among patients with diabetic drug-resistant tuberculosis.
    Putra ON; Yulistiani Y; Soedarsono S; Subay S
    Int J Mycobacteriol; 2023; 12(3):241-247. PubMed ID: 37721227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis.
    Sarin R; Vohra V; Singla N; Singla R; Puri MM; Munjal SK; Khalid UK; Myneedu VP; Verma A; Mathuria KK
    Indian J Tuberc; 2019 Jan; 66(1):184-188. PubMed ID: 30878066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis.
    Kwon YS
    Chonnam Med J; 2017 May; 53(2):103-109. PubMed ID: 28584788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.